Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 6 for:    ELND005
Previous Study | Return to List | Next Study

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

This study is enrolling participants by invitation only.
Elan Pharmaceuticals
Information provided by (Responsible Party):
Elan Pharmaceuticals ( Elan Pharma International Limited ) Identifier:
First received: January 8, 2013
Last updated: July 3, 2014
Last verified: July 2014

To evaluate the safety and tolerability of ELND005 treatment with up to 48 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.

Condition Intervention Phase
Alzheimer's Disease
Drug: Group 1 ELND005
Drug: Group 2 ELND005
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Elan Pharmaceuticals:

Primary Outcome Measures:
  • To evaluate the safety and tolerability of ELND005 treatment with up to 48 weeks exposure, in Moderate to Severe AD patients with agitation and aggression. [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    Incidence and severity of TEAEs, SAEs, and withdrawals due to AEs.

Estimated Enrollment: 400
Study Start Date: January 2013
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1 ELND005
Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks.
Drug: Group 1 ELND005
Experimental: Group 2 ELND005
Patients who received placebo during Study AG201 will receive ELND005 at a dose similar to the active group in Study AG201 for 36 weeks.
Drug: Group 2 ELND005


Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Complete Week 12 visit of AG201
  • Both patient and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests

Exclusion Criteria:

  • Is currently using any other investigational or experimental drugs or devices
  • Has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01766336

  Show 46 Study Locations
Sponsors and Collaborators
Elan Pharma International Limited
Elan Pharmaceuticals
  More Information

Additional Information:
No publications provided

Responsible Party: Elan Pharmaceuticals ( Elan Pharma International Limited ) Identifier: NCT01766336     History of Changes
Other Study ID Numbers: ELND005-AG251, 2012-005524-15
Study First Received: January 8, 2013
Last Updated: July 3, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Elan Pharmaceuticals:
AD patients

Additional relevant MeSH terms:
Alzheimer Disease
Behavioral Symptoms
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies processed this record on November 20, 2014